Home > Boards > US Listed > Biotechs > Opko Health Inc (OPK)

Rare Disease IDM Director Somatrogon

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Femto99 Member Profile
Member Level 
Followed By 43
Posts 4,142
Boards Moderated 10
Alias Born 02/22/18
160x600 placeholder
OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health ... PR Newswire (US) - 1/13/2021 3:40:00 PM
Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q’20 Guidance GlobeNewswire Inc. - 1/13/2021 6:00:00 AM
OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/5/2021 8:00:00 AM
OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide PR Newswire (US) - 1/4/2021 12:05:00 PM
Pfizer, OPKO: FDA to Review Somatrogon for Growth-Hormone Deficiency Dow Jones News - 1/4/2021 9:09:00 AM
US FDA Accepts Regulatory Submission from Pfizer & OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Horm... Business Wire - 1/4/2021 6:45:00 AM
Buffalo Bills and OPKO Health's BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Prog... PR Newswire (US) - 12/31/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/29/2020 7:34:20 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 8:09:54 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/21/2020 8:07:23 AM
OPKO Health Appoints Dr. Roger Medel to its Board of Directors GlobeNewswire Inc. - 12/21/2020 8:00:00 AM
Sian Capital Sends Letter to OPKO Health Regarding its Decision to Apparently Withhold Rayaldee From Many Patients Amidst COV... GlobeNewswire Inc. - 11/20/2020 4:45:00 PM
Sian Capital Issues Open Letter to Stockholders of OPKO Health GlobeNewswire Inc. - 11/12/2020 6:30:00 PM
OPKO Health to Participate in Three Upcoming Investment Conferences GlobeNewswire Inc. - 11/11/2020 9:10:51 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2020 6:57:26 AM
Sian Capital Highlights Paths to Meaningful Value Creation at OPKO Health GlobeNewswire Inc. - 10/29/2020 5:20:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/29/2020 4:26:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2020 4:08:24 PM
OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results GlobeNewswire Inc. - 10/29/2020 4:05:10 PM
OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test PR Newswire (US) - 10/20/2020 8:00:00 AM
OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020 GlobeNewswire Inc. - 10/13/2020 12:50:49 PM
OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools PR Newswire (US) - 10/9/2020 8:00:00 AM
Notice of Class Action Settlement Involving Purchasers of OPKO Health, Inc. Common Stock during the period of September 26, 2... PR Newswire (US) - 10/8/2020 9:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/15/2020 10:32:13 AM
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients GlobeNewswire Inc. - 9/15/2020 7:00:10 AM
Femto99 Member Level  Thursday, 09/17/20 06:42:41 PM
Re: None
Post # of 14345 
Rare Disease IDM Director Somatrogon
United Kingdom - Walton Oaks
Europe - Any Pfizer Site
Europe - Remote

Quote:
Pfizer has a long legacy in Growth Hormone space having launched Genotropin in 1986. Growth hormone deficiency is a rare disease characterized by the inadequate secretion of growth hormone from the pituitary gland and affects one in approximately 4,000 to 10,000 people. Somatrogon (Long Acting Growth Hormone) represents significant innovation and has the potential to provide an important treatment advance over the current standard of care for growth hormone deficiency, which requires once-daily injection. If approved, somatrogon could reduce the daily disease burden on children and their caregivers, potentially increasing treatment adherence. While the medicine has been developed in partnership with OPKO health, global commercialization is solely a Pfizer responsibility.

Global Marketing

Manage launch execution and readiness plan for IDM markets, working in partnership with the overall global brand launch execution lead

Develop IDM pricing and market access strategy in partnership with the PHI

Lead global competitive intelligence efforts for Growth Hormone, and translate IDM market specific insights to the region

Support overall Growth Hormone franchise strategy, including device strategy and co-positioning of Somatrogon and Genotropin, via the incorporation of deep IDM insights

Support IDM market specific pull-through of the branding, positioning and core campaign for the launch for Somatrogon





https://pfizer.wd1.myworkdayjobs.com/en-US/InternalJobs/job/United-Kingdom---Walton-Oaks/Rare-Disease-IDM-Director-Somatrogon_4792302

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences